1.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-C80405, C80405, SWOG-C80405, NCT00265850
|
|
2.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20080259, NCT00911170
|
|
3.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: DFCI-07070, 07-070, 7881, NCT00551421
|
|
4.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCIRVINE-UCI06-8-01, UCI06-8-01, NCT00754494
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20070411, NCT00819169
|
|
6.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR015580, NCT00841191
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 10354, NCT00920868
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3160A6-2208, NCT00959946
|
|
9.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20020715, NCT00094809
|
|
10.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: CINJ-3330, NCT00161187
|
|
11.
|
Phase: Phase II
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UPCC-09205, UPCC#09205, GENENTECH-UPCC-09205, UPCC-804021, NCT00602329
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: CO07201 (LAP109859), NCT00574171
|
|
13.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: UCI 07-47, NCT00578721
|
|
14.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ETH190-06, ETH190-06, NCT00601198
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10534, H6Q-MC-S064, NCT00612586
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: M10-300, EudraCT: 2007-007081-38, NCT00707889
|
|
17.
|
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: GRID, NCT00765570
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2004-0779, NCT00766220
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: NCI-2009-00947, CCCWFU 59109, NCT00904267
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EZN-2208-04, NCT00931840
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: RPCI I 152009, NCT01004159
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BrUOG-CR-218, NCT01057017
|
|
23.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: RPCI-I 55305, 6789, I 55305, NCI-6789, NCT00138177
|
|
24.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 174-2004, EU841-03, NCT00288444
|
|
25.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: IMMUNO-101, IMMUNO-045-5011-228, UTHSC-IDD-0504, NCT00352131
|
